Oncolytics Biotech Inc. (ONCY)

Market Cap	83.34M
Revenue (ttm)	n/a
Net Income (ttm)	-28.21M
Shares Out	75.42M
EPS (ttm)	-0.40
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	260,727
Open	1.150
Previous Close	1.130
Day's Range	1.100 - 1.150
52-Week Range	0.880 - 3.390
Beta	1.45
Analysts	Strong Buy
Price Target	5.50 (+395.5%)
Earnings Date	May 9, 2024

About ONCY

Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. It has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelare...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Nov 8, 1999
• Employees: 29
• Stock Exchange: NASDAQ
• Ticker Symbol: ONCY

Analyst Forecast

According to 4 analysts, the average rating for ONCY stock is "Strong Buy." The 12-month stock price forecast is $5.5, which is an increase of 395.50% from the latest price.

Price Target

$5.5

(395.50% upside)

Analyst Consensus: Strong Buy